MammoScreen for Breast Cancer Risk Assessment
This study is looking at how well a tool called MammoScreen works to assess breast cancer risk and guide screening decisions. MammoScreen is a questionnaire that helps identify women at average or increased risk for breast cancer. The study wants to see how many women use MammoScreen and how many women with above-average risk are identified when MammoScreen is connected to their electronic health record. You might be able to join if you are a woman between 40 and 74 years old, use MyChart, and can read English. You cannot join if you have a personal history of breast or ovarian cancer, are pregnant, or are in hospice. The study aims to understand if MammoScreen helps with breast cancer screening referrals and completed mammograms.
- Study design
- This is an observational study involving 1141 women. It is not a randomized trial, meaning participants are not assigned to different treatment groups.
- What's involved
- If you are a patient, your medical records will be reviewed, and you will be invited via MyChart to use MammoScreen. You may also participate in an interview lasting up to 1 hour.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track the uptake of MammoScreen and the identification of women with above-average risk for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Karen Eden, Ph.D. · PRINCIPAL_INVESTIGATOR · Department of Medical Informatics and Clinical Epidemiology, OHSU Knight Cancer Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Uptake of MammoScreenUp to 5 years
Defined as the proportion of women who enroll and use MammoScreen. Proportions of invitations for newly eligible women and uptake of MammoScreen during the maintenance period, overall and by clinical team, will be characterized along with 95% exact confidence intervals.
- Number of women with above-average risk for breast cancer identified by MammoScreen integrated with the electronic health recordUp to 5 years